NCT02149329View on ClinicalTrials.gov

Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO

PHASE4CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 5, 2019

Study Completion Date

August 5, 2019

Conditions
Febrile NeutropeniaHematological Malignancy
Interventions
DRUG

Discontinuation of imipenem-cilastatin or meropenem

Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.

Trial Locations (2)

1081 HV

VU university medical center, Amsterdam

Unknown

HAGA ziekenhuis, The Hague

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

FondsNutsOhra

UNKNOWN

lead

Amsterdam UMC, location VUmc

OTHER

NCT02149329 - Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO | Biotech Hunter | Biotech Hunter